ClinicalTrials.gg
CompletedNCT02873221Updated Aug 28, 2019Results posted

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

A Phase 3 interventional study of Ubrogepant and Placebo-matching Ubrogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 177 sites in United States. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,254
Allocation
Randomized
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
3rd of 14
1,254 · median 507
Started
2016
with 2 others
Phase 3
7 of 14
2 open now
Registered
5th of 14
by date
Lead sponsor
6 of 14
Allergan

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 5th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

Read the detailed description

Usual care is the open-label control arm. Dose of ubrogepant (50 mg or 100 mg) will be double-blind for active treatment arms.

03

Conditions studied

  • Migraine, With or Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).

Exclusion criteria

Exclusion Criteria:

  • Patients with (ECG), vital sign, physical exam, or laboratory abnormalities
  • Requirement for a medication during the study that is on the list of prohibited medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,254 participants (actual)

Study arms

  • Active comparator
    Usual Care

    Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.

    Drug: Usual Care

  • Experimental
    Ubrogepant 50 mg

    Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.

    Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant

  • Experimental
    Ubrogepant 100 mg

    Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.

    Drug: Ubrogepant

Interventions

  • Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  • DrugPlacebo-matching Ubrogepant

    Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.

  • DrugUsual Care

    Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Treatment Emergent Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs with an onset that occurs after receiving study drug.

    Time frame: 56 Weeks

Secondary outcomes

  1. Number of Participants With Clinically Significant Laboratory Values

    Hematology, Chemistry and Urinalysis results considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

    Time frame: 56 Weeks

  2. Number of Participants With Clinically Significant Electrocardiograms (ECGs) Findings

    ECG findings considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

    Time frame: 56 Weeks

  3. Number of Participants With Clinically Significant Vital Sign Measurements

    Vital sign measurements considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

    Time frame: 56 Weeks

  4. Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales

    On the C-SSRS, the 5 types of suicidal ideation are: Type 1: "Wish to be dead" Type 2: Non-specific active suicidal thoughts Type 3: "Active suicidal ideation with any methods (not plan) without intent to act" Type 4: "Active suicidal ideation with some intent to act, without specific plan" Type 5: "Active suicidal ideation with specific plan and intent"

    Time frame: 56 Weeks

07

Results

Posted Aug 28, 2019

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneUsual CareUbrogepant 50 mgUbrogepant 100 mg
Started417417420
Safety population: received study drug417404409
Completed329291315
Not completed88126105
Withdrew: Other miscellaneous reasons021
Withdrew: Non-compliance with study drug032
Withdrew: Protocol violation258
Withdrew: Pregnancy463
Withdrew: Lack of qualifying event031
Withdrew: Withdrawal of consent525141
Withdrew: Lack of efficacy01712
Withdrew: Adverse event4911
Withdrew: Lost to follow-up263026
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestoneUsual CareUbrogepant 50 mgUbrogepant 100 mg
Started350356364
Completed343339350
Not completed71714
Withdrew: Other miscellaneous reasons020
Withdrew: Protocol violation001
Withdrew: Lost to follow-up355
Withdrew: Withdrawal of consent4108

Outcome measures

PrimaryPercentage of Participants With at Least 1 Treatment Emergent Adverse Event

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs with an onset that occurs after receiving study drug.

Time frame:
56 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event
Percentage of ParticipantsUsual CareUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event6566.372.6
SecondaryNumber of Participants With Clinically Significant Laboratory Values

Hematology, Chemistry and Urinalysis results considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

Time frame:
56 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Values
ParticipantsUsual CareUbrogepant 50 mgUbrogepant 100 mg
Basophils Absolute Cell Count (10**9/L) >2×ULN000
Eosinophils Absolute Cell Count (10**9/L) >2×ULN101
Hematocrit (RATIO) <0.9×LLN326
Hematocrit (RATIO) >1.1×ULN201
Hemoglobin (g/L) <0.9×LLN736
Hemoglobin (g/L) >1.1×ULN201
Lymphocytes Absolute Cell Count (10**9/L) <0.7×LLN1155
Lymphocytes Absolute Cell Count (10**9/L) >1.3×ULN868
Monocytes Absolute Cell Count (10**9/L) <0.5×LLN000
Monocytes Absolute Cell Count (10**9/L) >2×ULN000
Neutrophils Absolute Cell Count (10**9/L) <0.7×LLN656
Neutrophils Absolute Cell Count (10**9/L) >1.3×ULN221417
Platelet Count (Thrombocytes) (10**9/L) <0.5×LLN000
Platelet Count (Thrombocytes) (10**9/L) >1.5×ULN221
Red Blood Cell Count (10**12/L) <0.9×LLN153
Red Blood Cell Count (10**12/L) >1.1×ULN222
White Blood Cell Count (10**9/L) <0.9×LLN17917
White Blood Cell Count (10**9/L) >1.5×ULN524
Alanine Aminotransferase (SGPT) (U/L) >3×ULN448
Albumin (g/L) <0.8×LLN010
Albumin (g/L) >1.2×ULN000
Alkaline Phosphatase (U/L) >3×ULN000
Aspartate Aminotransferase (SGOT) (U/L) >3×ULN229
Bicarbonate (HCO3) (mmol/L) <0.9×LLN252237
Bicarbonate (HCO3) (mmol/L) >1.1×ULN000
Bilirubin, Total (umol/L) >1.5×ULN342
Blood Urea Nitrogen (mmol/L) >1.5×ULN631
Calcium (mmol/L) <0.9×LLN213
Calcium (mmol/L) >1.1×ULN000
Chloride (mmol/L) <0.9×LLN001
Chloride (mmol/L) >1.1×UL000
Cholesterol, Total (mmol/L) >1.6×ULN412
Creatine Kinase (U/L) >2×ULN564357
Creatinine (umol/L) >1.5×ULN111
Glucose, Non-fasting (mmol/L) <0.8×LLN000
Glucose, Non-fasting (mmol/L) >2×ULN111
Lactate Dehydrogenase (U/L) >3×ULN000
Phosphorus (mmol/L) <0.9×LLN453842
Phosphorus (mmol/L) >1.1×ULN211521
Potassium (mmol/L) <0.9×LLN013
Potassium (mmol/L) >1.1×ULN283233
Protein, Total (g/L) <0.9×LLN324
Protein, Total (g/L) >1.1×ULN000
Sodium (mmol/L) <0.9×LLN000
Sodium (mmol/L) >1.1×ULN002
Triglycerides (mmol/L) >2×ULN302017
Uric Acid (Urate) (umol/L) >1.2×ULN262722
Glucose Positive211723
pH (pH) <0.9×LLN000
pH (pH) >1.1×ULN000
Protein (g/L) Positive000
Specific Gravity >1.1×ULN000
SecondaryNumber of Participants With Clinically Significant Electrocardiograms (ECGs) Findings

ECG findings considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

Time frame:
56 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiograms (ECGs) Findings
ParticipantsUsual CareUbrogepant 50 mgUbrogepant 100 mg
PR interval (msec) PR >= 250000
QRS interval (msec) QRS >= 150110
QTc Bazett (msec) QTcB > 500000
QTc Bazett (msec) Increase > 60 (msec)015
QTc Fridericia (msec) QTcF > 500000
QTc Fridericia (msec) Increase > 60 (msec)100
SecondaryNumber of Participants With Clinically Significant Vital Sign Measurements

Vital sign measurements considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.

Time frame:
56 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Measurements
ParticipantsUsual CareUbrogepant 50 mgUbrogepant 100 mg
SBP (mmHg) (Sitting) <= 90 and Decrease of >= 20112012
SBP (mmHg) (Sitting) >= 180 and Increase of >= 20001
SBP (mmHg) (Standing) <= 90 and Decrease of >= 20121111
SBP (mmHg) (Standing) >= 180 and Increase of >= 20001
Standing - Sitting SBP (mmHg) <= -20584049
DBP (mmHg) (Sitting) <= 50 and Decrease of >= 15654
DBP (mmHg) (Sitting) >= 105 and Increase of >= 15636
DBP (mmHg) (Standing) <= 50 and Decrease of >= 15544
DBP (mmHg) (Standing) >= 105 and Increase of >= 15121411
Standing - Sitting DBP (mmHg) <= -15384236
PR (beats/min) (Sitting) <= 50, Decrease of >= 15457
PR (beats/min) (Sitting) >= 120, Increase of >= 15121
PR (beats/min) (Standing) <= 50, Decrease of >= 15233
PR (beats/min)(Standing) >= 120, Increase of >= 1514913
Standing - Sitting Pulse Rate (beats/min) >= 25423735
Weight (kg) Decrease of >= 7%584853
Weight (kg) Increase of >= 7%736961
SecondaryNumber of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales

On the C-SSRS, the 5 types of suicidal ideation are: Type 1: "Wish to be dead" Type 2: Non-specific active suicidal thoughts Type 3: "Active suicidal ideation with any methods (not plan) without intent to act" Type 4: "Active suicidal ideation with some intent to act, without specific plan" Type 5: "Active suicidal ideation with specific plan and intent"

Time frame:
56 Weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales
ParticipantsUsual CareUbrogepant 50 mgUbrogepant 100 mg
Suicidal Ideation532
Suicidal Behavior000

Adverse events

Collected over Adverse events were collected up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care0/417 (0%)17/417 (4.1%)132/417 (31.7%)
Ubrogepant 50 mg0/404 (0%)9/404 (2.2%)125/404 (30.9%)
Ubrogepant 100 mg0/409 (0%)12/409 (2.9%)138/409 (33.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventUsual CareUbrogepant 50 mgUbrogepant 100 mg
Cholecystitis acuteHepatobiliary disorders0/4171/4041/409
CholelithiasisHepatobiliary disorders1/4171/4041/409
PneumoniaInfections and infestations1/4171/4041/409
Device allergyImmune system disorders0/4171/4040/409
Gait disturbanceGeneral disorders0/4171/4040/409
Hypertensive crisisVascular disorders0/4171/4040/409
Intestinal obstructionGastrointestinal disorders0/4171/4040/409
Pelvic inflammatory diseaseInfections and infestations0/4171/4040/409
Post procedural infectionInfections and infestations1/4171/4040/409
Sinus tachycardiaCardiac disorders0/4171/4040/409
Most frequent other events
Most frequent other events
EventUsual CareUbrogepant 50 mgUbrogepant 100 mg
Upper respiratory tract infectionInfections and infestations48/41747/40444/409
NasopharyngitisInfections and infestations33/41733/40447/409
SinusitisInfections and infestations25/41728/40426/409
Urinary tract infectionInfections and infestations23/41722/40426/409
InfluenzaInfections and infestations21/41717/40425/409

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(Years)Usual CareUbrogepant 50 mgUbrogepant 100 mgTotal
Mean41.7 ± 11.742.2 ± 12.241.2 ± 11.241.7 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareUbrogepant 50 mgUbrogepant 100 mgTotal
Female3673843751126
Male503345128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Usual CareUbrogepant 50 mgUbrogepant 100 mgTotal
White3563583451059
Black or African American505261163
Asian32510
American Indian or Alaska Native4239
Native Hawaiian/Other Pacific Islander0123
Multiple42410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Usual CareUbrogepant 50 mgUbrogepant 100 mgTotal
Hispanic or Latino626459185
Not Hispanic or Latino3553533611069
08

Study locations

177 sites
  • Radiant Research, Inc.
    Birmingham, Alabama 35211, United States
  • East Family Physicians PC/Radiant Research, Inc.
    Chandler, Arizona 85224, United States
  • Desert Clinical Research /Radiant Research, Inc.
    Mesa, Arizona 85213, United States
  • Xenoscience, Inc.
    Phoenix, Arizona 85004, United States
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Radiant Research Inc.
    Tucson, Arizona 85712, United States
  • Orange Grove Family Practice/Radiant Research, Inc.
    Tucson, Arizona 85741, United States
  • Principals Research Group, Inc.
    Hot Springs, Arkansas 71901, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Axiom Research
    Apple Valley, California 92307, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Med Center Medical Clinic Carmichael
    Carmichael, California 95608, United States
  • Axiom Research, LLC
    Colton, California 92324, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Encino Research Center/T Joseph Raoof MD Inc
    Encino, California 91436, United States
  • Neuro-Pain Medical Center, Inc
    Fresno, California 93710, United States
  • California Headache and Balance Center
    Fresno, California 93720, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Grossmont Center For Clinical Research
    La Mesa, California 91942, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90270, United States
  • Pacific Institute of Medical Research
    Los Angeles, California 90024, United States
  • Synergy San Diego
    National City, California 91950, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Newport Beach Clinical Research Associates, Inc.
    Newport Beach, California 92663, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • Desert Valley Research
    Rancho Mirage, California 92270, United States
  • George J Rederich MD, Inc.
    Redondo Beach, California 90277, United States
  • Artemis Institute For Clinical Research
    San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Southern California Research Center
    Simi Valley, California 93065, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Radiant Research
    Vista, California 92083, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Clinicos LLC
    Colorado Springs, Colorado 80904, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • Delta Waves, Inc
    Colorado Springs, Colorado 80918, United States
  • Denver Neurological Research
    Denver, Colorado 80210, United States
  • Summit Headache and Neurologic Institute
    Englewood, Colorado 80113, United States
  • Advanced Neurosciences Research
    Fort Collins, Colorado 80528, United States
  • Associated Neurologists, PC
    Danbury, Connecticut 06810, United States
  • Associated Neurologists of Southern Connecticut, PC
    Fairfield, Connecticut 06824, United States
  • Aventura Neurological Associates, PA
    Aventura, Florida 33180, United States
  • Clinical Research South Florida
    Coral Gables, Florida 33134, United States
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Wilks & Safirstein MD PA D/B/A MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Infinity Clinical Research
    Hollywood, Florida 33021, United States
  • Broward Research
    Hollywood, Florida 33024, United States
  • Clinical Neuroscience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Neurology Associates, P.A.
    Maitland, Florida 32751, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • LCC Medical Research
    Miami, Florida 33126, United States
  • Well Pharma Medical Research
    Miami, Florida 33143, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • Clinical Neuroscience Solutions, Inc - Memphis, TN
    Orlando, Florida 32801, United States
  • Palm Beach Neurological Center / Advanced Research Consultants, Inc.
    Palm Beach Gardens, Florida 33410, United States
  • Qps Mra, Llc
    South Miami, Florida 33143, United States
  • Meridien Research
    Spring Hill, Florida 34609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Neurology Research Institute Palm Beach
    West Palm Beach, Florida 33407, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Midtown Neurology
    Atlanta, Georgia 30312, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30342, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Michigan Ave. Internists /Radiant Research, Inc.
    Chicago, Illinois 60604, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Great Lakes Clinical Trials, LLC
    Chicago, Illinois 60640, United States
  • Robbins Headache Clinic
    Riverwoods, Illinois 60015, United States
  • Deaconess Clinic Inc.
    Evansville, Indiana 47713, United States
  • Josephson Wallack Munshower Neurology, P.C.
    Indianapolis, Indiana 46256, United States
  • Rowe Neurology Institute
    Lenexa, Kansas 66214, United States
  • College Park Family Care Center Physicians Group- Neurology Research Dept
    Overland Park, Kansas 66210, United States
  • Kansas Institute of Research
    Overland Park, Kansas 66211, United States
  • Kentucky Pediatric Research Inc
    Bardstown, Kentucky 40004, United States
  • Norton Neurology Services
    Louisville, Kentucky 40207, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Pharma Site Research
    Baltimore, Maryland 21208, United States
  • Seton Medical Group
    Baltimore, Maryland 21228, United States
  • Boston Clinical Trials Inc
    Boston, Massachusetts 02131, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02470, United States
  • Northeast Medical Research Associates, Inc.
    North Dartmouth, Massachusetts 02747, United States
  • Beacon Clinical Research, LLC
    Quincy, Massachusetts 02169, United States
  • Medvadis Research Corporation
    Watertown, Massachusetts 02472, United States
  • New England Regional Headache Center
    Worcester, Massachusetts 01605, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Women's Health Care Specialists
    Kalamazoo, Michigan 49009, United States
  • The Minneapolis Clinic of Neurology, Ltd.
    Golden Valley, Minnesota 55422, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States

Showing the first 100 of 177 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lipton RB, Dodick DW, Goadsby PJ, Burstein R, Adams AM, Lai J, Yu SY, Finnegan M, Kuang AW, Trugman JM. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain. Neurology. 2022 Oct 25;99(17):e1905-e1915. doi: 10.1212/WNL.0000000000201031. Epub 2022 Aug 17. PubMed 35977836 ↗
  • Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2022 Jan;39(1):692-705. doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 7. PubMed 34874514 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Aug 2018, 22 months.

Results were first posted in Aug 2019, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 22 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Aug 19, 2016
StartActual
Sep 13, 2016
Primary completionActual
Aug 2, 2018
CompletionActual
Aug 2, 2018
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02873221
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Aug 19, 2016
Start date
Sep 13, 2016
Primary completion
Aug 2, 2018
Completion
Aug 2, 2018
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Study contacts

Adele Thorpe
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion